Garry Cooper
Affiliations: | Physiology and Chemistry | Northwestern University, Evanston, IL |
Area:
LTCC pharmacology in PDGoogle:
"Garry Cooper"Mean distance: 15.36 (cluster 6) | S | N | B | C | P |
Cross-listing: Chemistry Tree
Parents
Sign in to add mentor| D. James Surmeier | grad student | 2008-2014 | Northwestern | |
| (Novel Selective Neuronal L-type Calcium Channel Inhibitors as Potential Therapeutics in Parkinson's Disease.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cooper G, Kang S, Perez-Rosello T, et al. (2021) Correction to A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca1.3 L-Type Calcium Channels. Acs Chemical Biology |
| Cooper G, Kang S, Perez-Rosello T, et al. (2020) A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of Ca1.3 L-Type Calcium Channels. Acs Chemical Biology |
| Cooper G, Lasser-Katz E, Simchovitz A, et al. (2015) Functional segregation of voltage-activated calcium channels in motoneurons of the dorsal motor nucleus of the vagus. Journal of Neurophysiology. 114: 1513-20 |
| Xu W, Hong SJ, Zeitchek M, et al. (2015) Hydration status regulates sodium flux and inflammatory pathways through epithelial sodium channel (ENaC) in the skin. The Journal of Investigative Dermatology. 135: 796-806 |
| Kang S, Cooper G, Dunne SF, et al. (2013) Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. Bioorganic & Medicinal Chemistry. 21: 4365-73 |
| Kang S, Cooper G, Dunne SF, et al. (2013) Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. Journal of Medicinal Chemistry. 56: 4786-97 |
| Kang S, Cooper G, Dunne SF, et al. (2012) CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nature Communications. 3: 1146 |